Latest news and research on all cancers and treatments, updated several times a week
The addition of the investigational agent TH-302 to gemcitabine significantly improved PFS, tumor response and CA 19-9 response in patients with ...
Pancreatic cancer is the fourth leading cause of cancer deaths in the developed world and its incidence is rising. Unfortunately, it is often described as ...
TRVX: Targovax Reports Completion of Recruitment of Patients in the Phase I/II Clinical Trial CT ...
TG01 has Orphan Drug status for pancreatic cancer in the EU and US and is currently in Phase II trials in operated pancreatic cancer. The company is ...
And the risk of stroke is higher among those with more aggressive cancer, ... diagnosed with breast, colorectal, lung, prostate and pancreatic cancer.
PharmaCyte Biotech's treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated ...
More divisions means more mutations and perhaps more cancers. ... of oesophageal cancer, 37% of bladder cancer and 29% of pancreatic cancer), ...
... Company's products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, ...
“The immune system plays an important role in cancer development and control, and we're learning through scientific research how the two are ...
By day, Jake Sheppard is a Boulder-based scientist, studying how the immunesystem interacts with cancer, using gene-editing software to explore ...
For example, an innovative "anti-cancer hat" has been so successful that ... this approach uses a person's own immune system to attack their cancer.
Bostwick Laboratories' lab developed test, which includes the telomerase stain for bladder cancer, CytologyPro XT will be launched today. -Bostwick ...
The company also declared it is initiating Phase 2 clinical trials with BIND-014 in cholangiocarcinoma, cervical cancer, bladder cancer, and head and ...
Bladder cancer (BC) presents with an estimate of 72,570 new cases diagnosed and 15,210 deaths across the United States [1] in the year 2013, ...
Surface wants to develop cancer immunotherapies, but acting CEO Dave Grayzel says it's got different ideas than Juno Therapeutics (NASDAQ: ...
Breakthroughs in cancer research have a long history of being overhyped. But the enthusiasm for immunotherapy is different. It's exciting because ...
Incyte and Agenus said today they will develop and commercialize cancer immunotherapeutics by using the latter's Retrocyte Display™ antibody ...
Using the same technology as its HIV treatment, AGS-003 is an immunotherapy that uses a patient's own dendritic cells to fight cancer growth, and it's ...
Forbes
Cancer Research Institute Suggests Cancer Cure Could Come ... which focuses its research budget on promising cancer immunotherapy research.
Driving Cancer Immunotherapy Manager's Choice. The Scientist brings ..
Treating Depression in Cancer Patients
According to three associated and recently published large randomized studies, while about 75% of cancer patients with major depression do not receive any treatment for their depression, a new system of integrating depression treatment into cancer care can transform patient outcomes.
According to three associated and recently published large randomized studies, while about 75% of cancer patients with major depression do not receive any treatment for their depression, a new system of integrating depression treatment into cancer care can transform patient outcomes.
Can Testosterone Treat Prostate Cancer?
A small study found that paradoxically, testosterone may suppress the growth of some advanced prostate cancers and could reverse resistance to testosterone-blocking agents.
A small study found that paradoxically, testosterone may suppress the growth of some advanced prostate cancers and could reverse resistance to testosterone-blocking agents.
T-DM1 Trial Disappoints in HER2-Positive Breast Cancer
Results of the MARIANNE trial found that HER2-positive breast cancer patients treated with T-DM1 had similar survival to those on the current standard of care.
Results of the MARIANNE trial found that HER2-positive breast cancer patients treated with T-DM1 had similar survival to those on the current standard of care.
PIK3CA Mutations Matter in HER2-Positive Breast Cancer
Two recently published studies suggest that PIK3CA mutations cannot be used as a predictive biomarker to guide therapy in HER2-positive breast cancer.
Two recently published studies suggest that PIK3CA mutations cannot be used as a predictive biomarker to guide therapy in HER2-positive breast cancer.
Bisphosphonates May Cut Risk of Endometrial Cancer
An analysis of a large number of women suggested that those who use bisphosphonates, a bone medication used to treat osteoporosis and other bone loss diseases, have a reduced risk of endometrial cancer.
An analysis of a large number of women suggested that those who use bisphosphonates, a bone medication used to treat osteoporosis and other bone loss diseases, have a reduced risk of endometrial cancer.
Cancer News in Science Daily
Evaluators report that data on survival were not evaluable because group differences might have been caused by the circumstances of the subsequent therapies when reviewing the potential added benefit of Sipulecuel-T. Certain side effects such as fever were found to be more frequent.
An innovative combination therapy against metastases is under development. Researchers treated mice with a combination of a low-dose metronomic chemotherapy and an antibody against Ang-2, a regulatory protein of the blood vessel lining cells. The treated animals had significantly less metastases.
An intervention designed to provide Latina breast cancer survivors with the knowledge and skills needed to change and sustain dietary behaviors helps survivors adhere to recommended guidelines to eat a diet high in fruits and vegetables. Using a culturally based hands-on educational approach, the program is geared toward Latina breast cancer survivors whose are at higher risk of high obesity rates, low physical activity rates, and poorer access to quality healthcare.
HPV testing alone is an effective alternative to current cervical cancer screening methods that use a Pap smear, or Pap smear-plus HPV test, according to new new interim guidance written by a group of cervical cancer screening experts.
Looking at whether a man’s uncles and great-grandparents, among other second- and third-degree relatives, had prostate cancer could be as important as looking at whether his father had prostate cancer. A more complete family history would give physicians a new tool to decide whether or not a PSA test was appropriate, experts say.
Tambahkan Komentar